Roche: UBS still on hold

(CercleFinance.com) - UBS believes that its IMbrave050 treatment is "clinically relevant but less commercially successful".


The broker maintains its neutral rating on the stock with an unchanged target price of 315 Swiss francs (cp: 294 Swiss francs, -0.2%).

Note that the phase III IMbrave050 study of Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence after surgery met its primary endpoint.

In the interim analysis of this study, the Tecentriq-Avastin combination showed a statistically significant improvement in liver cancer recurrence-free survival compared to active surveillance.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.